Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 56.00 | |
2 mg | In stock | $ 79.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 198.00 | |
25 mg | In stock | $ 369.00 | |
50 mg | In stock | $ 531.00 | |
100 mg | In stock | $ 768.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 156.00 |
Description | BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively. |
Targets&IC50 | BCR-ABL (T315I):0.590 μM, c-ABL (T334I):0.25 μM, BCR-ABL:0.09 μM |
Synonyms | K 0859 |
Molecular Weight | 578.58 |
Formula | C30H29F3N6O3 |
CAS No. | 890129-26-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (216.05 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BGG463 890129-26-7 Angiogenesis Cell Cycle/Checkpoint Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl CDK K03859 inhibit Cyclin dependent kinase Inhibitor K 0859 K 03859 K0859 K-0859 K-03859 BGG 463 BGG-463 inhibitor